164 related articles for article (PubMed ID: 4019118)
21. Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity.
Perren TJ; Blackledge G; Mould JJ; Chetiyawardana AD; Morrison M; Hancock A
Invest New Drugs; 1985; 3(2):173-7. PubMed ID: 3926713
[TBL] [Abstract][Full Text] [Related]
22. Mitoxantrone and cyclophosphamide in patients with advanced breast cancer.
Ehninger G; Weible KH; Heidemann EG; Waller HD
Cancer Treat Rep; 1984 Oct; 68(10):1283-4. PubMed ID: 6525600
[TBL] [Abstract][Full Text] [Related]
23. Mitoxantrone: an active new agent in the treatment of advanced breast cancer.
Stuart-Harris RC; Bozek T; Pavlidis NA; Smith IE
Cancer Chemother Pharmacol; 1984; 12(1):1-4. PubMed ID: 6690066
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
Arseneau JC; Schoenfeld DA; Borden EC
Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041
[TBL] [Abstract][Full Text] [Related]
25. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
[TBL] [Abstract][Full Text] [Related]
26. Phase II studies of mitoxantrone in patients with primary liver cancer.
Falkson G; Coetzer BJ
Invest New Drugs; 1985; 3(2):187-9. PubMed ID: 4019121
[TBL] [Abstract][Full Text] [Related]
27. [Phase II study of mitoxantrone in advanced breast cancer].
Ogawa M; Kubo K; Tominaga T; Nomura Y; Ota K; Yoshida M; Taguchi T; Hoshino A
Gan To Kagaku Ryoho; 1986 May; 13(5):1980-4. PubMed ID: 3707156
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of mitoxantrone on a daily X 5 schedule.
Goldsmith MA; Ohnuma T; Jaffrey IH; Greenspan EM; Holland JF
Am J Clin Oncol; 1984 Oct; 7(5):567-70. PubMed ID: 6507380
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.
Ford JM; Panasci L; Leclerc Y; Margolese R
Cancer Treat Rep; 1987 Oct; 71(10):921-5. PubMed ID: 3308079
[TBL] [Abstract][Full Text] [Related]
30. Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Martoni A; Rani P; Ercolino L; Canova N; Pannuti F
Chemioterapia; 1988 Oct; 7(5):345-9. PubMed ID: 3224403
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
[TBL] [Abstract][Full Text] [Related]
32. [Mitoxantrone in a combination regimen in advanced breast cancer].
Hausmaninger H
Wien Med Wochenschr; 1985 Dec; 135(23-24):594-7. PubMed ID: 4096006
[TBL] [Abstract][Full Text] [Related]
33. Mitoxantrone in refractory acute leukemia in children: a phase I study.
Starling KA; Mulne AF; Vats TS; Schoch I; Dukart G
Invest New Drugs; 1985; 3(2):191-5. PubMed ID: 4019122
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of mitoxantrone in acute leukemia.
Masaoka T; Shibata H; Oguma S; Nagai K; Kitani T; Horiuchi A; Yasunaga K; Yonezawa T; Kawagoe H
Invest New Drugs; 1985; 3(2):197-201. PubMed ID: 3860489
[TBL] [Abstract][Full Text] [Related]
35. Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Samonigg H; Stöger H; Kasparek AK; Schmid M; Dusleag J; Pfeiffer K; Smola M; Steindorfer P; Lechner P
Cancer Chemother Pharmacol; 1991; 27(6):477-80. PubMed ID: 2013118
[TBL] [Abstract][Full Text] [Related]
36. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
Henderson IC; Allegra JC; Woodcock T; Wolff S; Bryan S; Cartwright K; Dukart G; Henry D
J Clin Oncol; 1989 May; 7(5):560-71. PubMed ID: 2468745
[TBL] [Abstract][Full Text] [Related]
37. A comparison of mitoxantrone and doxorubicin in breast cancer.
Neidhart JA; Gochnour D; Roach R; Hoth D; Young D
J Clin Oncol; 1986 May; 4(5):672-7. PubMed ID: 3517241
[TBL] [Abstract][Full Text] [Related]
38. Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.
Mouridsen HT; Andersson M; Pedersen L
Semin Oncol; 1986 Mar; 13(1 Suppl 1):39-41. PubMed ID: 3952520
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of mitoxantrone in advanced breast cancer.
Pronzato P; Ardizzoni A; Conte PF; Gulisano M; Lionetto R; Repetto L; Scornavacche V; Sertoli MR; Rosso R
Chemioterapia; 1986 Jun; 5(3):150-3. PubMed ID: 3719852
[TBL] [Abstract][Full Text] [Related]
40. Clinical safety and tolerance of mitoxantrone.
Crossley RJ
Semin Oncol; 1984 Sep; 11(3 Suppl 1):54-8. PubMed ID: 6385266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
